Display options
Cite
Üçler R, Atmaca M, Candar Ö, et al. Development of Agranulocytosis after Discontinuation of Methimazole: An Unusual Case. Case Rep Endocrinol. 2015;2015:974524doi: 10.1155/2015/974524.
Üçler, R., Atmaca, M., Candar, �. �., Alay, M., Göy, B., Kara, E., Turan, M., & Demir, Y. (2015). Development of Agranulocytosis after Discontinuation of Methimazole: An Unusual Case. Case reports in endocrinology, 2015974524. https://doi.org/10.1155/2015/974524
Üçler, Rıfkı, et al. "Development of Agranulocytosis after Discontinuation of Methimazole: An Unusual Case." Case reports in endocrinology vol. 2015 (2015): 974524. doi: https://doi.org/10.1155/2015/974524
Üçler R, Atmaca M, Candar Ö, Alay M, Göy B, Kara E, Turan M, Demir Y. Development of Agranulocytosis after Discontinuation of Methimazole: An Unusual Case. Case Rep Endocrinol. 2015;2015:974524. doi: 10.1155/2015/974524. Epub 2015 Aug 03. PMID: 26339512; PMCID: PMC4538967.
Copy Download .nbib Format: NLM
Share it on

Case Rep Endocrinol. 2015;2015:974524. doi: 10.1155/2015/974524. Epub 2015 Aug 03.

Development of Agranulocytosis after Discontinuation of Methimazole: An Unusual Case.

Case reports in endocrinology

Rıfkı Üçler, Murat Atmaca, Ömer Candar, Murat Alay, Burhan Göy, Erdal Kara, Mahfuz Turan, Yusuf Demir

Affiliations

  1. Department of Endocrinology and Metabolism, Yuzuncu Yil University Faculty of Medicine, 65080 Van, Turkey.
  2. Department of Internal Medicine, Yuzuncu Yil University Faculty of Medicine, 65080 Van, Turkey.
  3. Department of Internal Medicine, Bulan?k State Hospital, 49500 Mus, Turkey.
  4. Department of Hematology, Yuzuncu Yil University Faculty of Medicine, 65080 Van, Turkey.
  5. Department of Otorhinolaryngology, Yuzuncu Yil University Faculty of Medicine, 65080 Van, Turkey.
  6. Department of Nuclear Medicine, Yuzuncu Yil University Faculty of Medicine, 65080 Van, Turkey.

PMID: 26339512 PMCID: PMC4538967 DOI: 10.1155/2015/974524

Abstract

Agranulocytosis is a rare and critical adverse effect of antithyroid drugs (ATD). The occurrence of agranulocytosis in continuous ATD treatment patients is well known; however, a case of ATD agranulocytosis occurring following the discontinuation of methimazole (MMI) treatment is not a usual situation. We herein describe a case of a 41-year-old woman who was previously administered methimazole (MMI) for ten days and developed ATD-induced agranulocytosis and symptoms of an upper respiratory tract infection after three weeks following discontinuation of MMI treatment. A thorough hematologic and serological evaluation did not disclose an alternative cause for the agranulocytosis. After receiving empirical antibiotic treatment, she responded successfully with clinical improvement of her symptoms and resolved neutropenia on the seventh day. This case is atypical because agranulocytosis developed after discontinuation of MMI, which strengthens the importance of remaining alert for signs of agranulocytosis even after discontinuation of ATD treatment.

References

  1. Exp Ther Med. 2014 Sep;8(3):823-825 - PubMed
  2. N Engl J Med. 1984 Nov 22;311(21):1353-62 - PubMed
  3. Br J Haematol. 1989 Jun;72(2):127-32 - PubMed
  4. Clin Endocrinol (Oxf). 1989 May;30(5):525-30 - PubMed
  5. Thyroid. 2004 Jun;14(6):459-62 - PubMed
  6. J Clin Endocrinol Metab. 2013 Dec;98(12):4776-83 - PubMed
  7. Semin Hematol. 1973 Oct;10(4):279-310 - PubMed
  8. J Clin Endocrinol Metab. 1995 Apr;80(4):1203-6 - PubMed
  9. Endocrinol Jpn. 1986 Oct;33(5):605-15 - PubMed

Publication Types